Carolina Moretto Carnielli

Dr. Carolina Moretto Carnielli

Brazilian Biosciences National Laboratory, Campinas, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
CCCarolina Moretto Carnielli
Carolina Moretto Carnielli
CMCarolina Carneiro Soares Macedo
Carolina Carneiro Soares Macedo
TRTatiane De Rossi
Tatiane De Rossi
DGDaniela Campos Granato
Daniela Campos Granato
CRCésar Rivera
César Rivera
ALAdriana Franco Paes Leme
Adriana Franco Paes Leme
Different regions of oral squamous cell carcinoma (OSCC) have particular histopathological and molecular characteristics limiting the standard tumor−node−metastasis prognosis classification. Therefore, defining biological signatures that allow assessing the prognostic outcomes for OSCC patients would be of great clinical significance. Using histopathology-guided discovery proteomics, we analyze neoplastic islands and stroma from the invasive tumor front (ITF) and inner tumor to identify differentially expressed proteins. Potential signature proteins are prioritized and further investigated by immunohistochemistry (IHC) and targeted proteomics. IHC indicates low expression of cystatin-B in neoplastic islands from the ITF as an independent marker for local recurrence. Targeted proteomics analysis of the prioritized proteins in saliva, combined with machine-learning methods, highlights a peptide-based signature as the most powerful predictor to distinguish patients with and without lymph node metastasis. In summary, we identify a robust signature, which may enhance prognostic decisions in OSCC and better guide treatment to reduce tumor recurrence or lymph node metastasis.

13 January 2016 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
EBElizabete Bagordakis
Elizabete Bagordakis
ISIris Sawazaki-Calone
Iris Sawazaki-Calone
CMCarolina Carneiro Soares Macedo
Carolina Carneiro Soares Macedo
CCCarolina Moretto Carnielli
Carolina Moretto Carnielli
COCarine Ervolino de Oliveira
Carine Ervolino de Oliveira
Ricardo D. ColettaRicardo D. Coletta
Ricardo D. Coletta

24 May 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
HRHelder V. Ribeiro-Filho
Helder V. Ribeiro-Filho
LCLais D. Coimbra
Lais D. Coimbra
ACAlexandre Cassago
Alexandre Cassago
RRRebeca P. F. Rocha
Rebeca P. F. Rocha
JGJoão Victor da Silva Guerra
João Victor da Silva Guerra
RMRafael Elias Marques
Rafael Elias Marques
Mayaro virus (MAYV) is an emerging arbovirus of the Americas that may cause a debilitating arthritogenic disease. The biology of MAYV is not fully understood and largely inferred from related arthritogenic alphaviruses. Here, we present the structure of MAYV at 4.4 Å resolution, obtained from a preparation of mature, infective virions. MAYV presents typical alphavirus features and organization. Interactions between viral proteins that lead to particle formation are described together with a hydrophobic pocket formed between E1 and E2 spike proteins and conformational epitopes specific of MAYV. We also describe MAYV glycosylation residues in E1 and E2 that may affect MXRA8 host receptor binding, and a molecular “handshake” between MAYV spikes formed by N262 glycosylation in adjacent E2 proteins. The structure of MAYV is suggestive of structural and functional complexity among alphaviruses, which may be targeted for specificity or antiviral activity.

1 January 2015 in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
Verified
Journal Article
Closed access
CCCarolina Moretto Carnielli
Carolina Moretto Carnielli
Flavia Vischi WinckFlavia Vischi Winck
Flavia Vischi Winck
ALAdriana F. Paes Leme
Adriana F. Paes Leme

1 August 2021 in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
Verified
Journal Article
Closed access
DGDaniela C. Granato
Daniela C. Granato
LNLeandro X. Neves
Leandro X. Neves
LTLuciana D. Trino
Luciana D. Trino
CCCarolina Moretto Carnielli
Carolina Moretto Carnielli
ALAriane F.B. Lopes
Ariane F.B. Lopes
ALAdriana F. Paes Leme
Adriana F. Paes Leme

15 December 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RKRebeca Kawahara
Rebeca Kawahara
DGDaniela C. Granato
Daniela C. Granato
CCCarolina Moretto Carnielli
Carolina Moretto Carnielli
NCNilva K. Cervigne
Nilva K. Cervigne
COCarine E. Oliveria
Carine E. Oliveria
ALAdriana Franco Paes Leme
Adriana Franco Paes Leme
Oral squamous cell carcinoma is the most common type of cancer in the oral cavity, representing more than 90% of all oral cancers. The characterization of altered molecules in oral cancer is essential to understand molecular mechanisms underlying tumor progression as well as to contribute to cancer biomarker and therapeutic target discovery. Proteoglycans are key molecular effectors of cell surface and pericellular microenvironments, performing multiple functions in cancer. Two of the major basement membrane proteoglycans, agrin and perlecan, were investigated in this study regarding their role in oral cancer. Using real time quantitative PCR (qRT-PCR), we showed that agrin and perlecan are highly expressed in oral squamous cell carcinoma. Interestingly, cell lines originated from distinct sites showed different expression of agrin and perlecan. Enzymatically targeting chondroitin sulfate modification by chondroitinase, oral squamous carcinoma cell line had a reduced ability to adhere to extracellular matrix proteins and increased sensibility to cisplatin. Additionally, knockdown of agrin and perlecan promoted a decrease on cell migration and adhesion, and on resistance of cells to cisplatin. Our study showed, for the first time, a negative regulation on oral cancer-associated events by either targeting chondroitin sulfate content or agrin and perlecan levels.